Welcome to our dedicated page for Arrowhead Pharma news (Ticker: ARWR), a resource for investors and traders seeking the latest updates and insights on Arrowhead Pharma stock.
Arrowhead Pharmaceuticals develops and commercializes RNA interference medicines that silence genes associated with intractable diseases. The company’s TRiM™ platform is used to design targeted RNAi therapeutics for tissues including liver, lung, muscle, adipose and central nervous system tissue.
Recurring ARWR news covers REDEMPLO® (plozasiran), an siRNA medicine approved in the United States and Australia as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome. Company updates also address plozasiran data across hypertriglyceridemia, regulatory actions in additional geographies, pricing and market-access strategy, fiscal results, investor events, and clinical or partnering developments involving programs such as ARO-PNPLA3, ARO-INHBE and ARO-ALK7.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) will host a webcast and conference call on May 4, 2021, at 4:30 p.m. ET to discuss its financial results for the fiscal second quarter ended March 31, 2021. Investors can join via the company's website or by dialing in. A replay will be available after the call for 90 days. Arrowhead is focused on developing RNAi-based therapeutics aimed at treating intractable diseases through gene silencing.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced ARO-DUX4, its first muscle-targeted investigational RNAi therapeutic candidate, aimed at treating facioscapulohumeral muscular dystrophy (FSHD). ARO-DUX4 targets the DUX4 gene, a known cause of muscle degeneration in FSHD. Preclinical data, to be presented at the 28th Annual FSHD Society International Research Congress, indicates ARO-DUX4 can reduce DUX4 expression by over 70%. Arrowhead plans to file for regulatory clearance in Q3 2021 for clinical studies, enhancing its pipeline beyond liver-targeted therapies.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced the submission of an Investigational New Drug Application (IND) for ARO-APOC3, aimed at treating hypertriglyceridemia. Initial studies showed up to a 92% reduction in triglycerides after two doses. Pending FDA review, the company plans to launch Phase 2b and Phase 3 clinical trials targeting severe hypertriglyceridemia and mixed dyslipidemia. These advancements underscore the potential of ARO-APOC3 as a new treatment for patients experiencing severe triglyceride elevation.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) reported its fiscal first quarter results for the period ended December 31, 2020. The company generated $21.3 million in revenue, down from $29.5 million in the same quarter of 2019. Operating expenses increased to $45.4 million, leading to a net loss of $20.7 million or $0.20 per share, compared to a loss of $2.7 million or $0.03 per share in the previous year. The firm is advancing its clinical pipeline with ongoing trials and collaborations, including a significant agreement with Takeda.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) has submitted an Investigational New Drug Application to the FDA for a Phase 2b study of ARO-ANG3, targeting mixed dyslipidemia. The trial aims to evaluate the safety and efficacy of the RNA interference therapeutic, focusing on reducing triglycerides and LDL cholesterol. The upcoming AROANG3-2001 study will enroll 180 participants to establish an effective dosing regimen. CMO Javier San Martin emphasized the need for new therapies in cardiovascular care, highlighting promising preliminary clinical data.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced a webcast and conference call scheduled for February 4, 2021, at 4:30 p.m. EST to discuss its financial results for the fiscal first quarter ending December 31, 2020. Investors can access the live audio webcast on the Company's website. A replay will be available for 90 days post-call. Arrowhead specializes in developing RNA interference-based therapeutics targeting intractable diseases through innovative gene silencing techniques.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced inducement grants for 27 new employees, approved on December 4, 2020. The grants include options to purchase 145,000 shares at a strike price of $65.29 and the potential for 96,000 restricted stock units (RSUs). These grants are outside the stockholder-approved equity incentive plans and will vest over four years. Arrowhead focuses on RNA interference therapies targeting intractable diseases, leveraging gene silencing to effectively treat conditions.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) will participate in key upcoming events. The Piper Sandler 32nd Annual Virtual Healthcare Conference occurs from December 1-3, 2020, featuring a presentation by CEO Chris Anzalone on December 2. Additionally, at the 20th Gordon L. Snider Critical Issues Workshop on December 12, James Hamilton, M.D., will discuss Arrowhead’s gene silencing approach for liver disease in Alpha-1 antitrypsin deficiency. Webcast links and materials are accessible on the company's Events and Presentations page.
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced that the collaboration and license agreement with Takeda Pharmaceutical Company Limited has officially closed. This closing was contingent upon review under U.S. antitrust laws, including the Hart-Scott-Rodino Act. Arrowhead focuses on developing RNA interference-based therapies to treat intractable diseases, leveraging its portfolio of RNA chemistries for gene silencing.
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported fiscal year 2020 results showing a significant revenue decline to $87.99 million from $168.80 million in 2019. The operating loss widened to $93.16 million, with a net loss of $84.55 million, translating to a diluted loss per share of $0.84. However, the company received a $20 million milestone from Amgen and achieved a strategic partnership with Takeda, including $300 million upfront and up to $740 million in milestones. Cash resources increased to $452.98 million, bolstering its financial position despite operating challenges.